Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study.

ABSTRACT:

Objectives

Subcutaneous administration of pertuzumab and trastuzumab offers a faster alternative to intravenous infusion for patients with HER2-positive breast cancer. However, real-world data on its impact on costs and capacity remain limited. Therefore, this study aimed to compare healthcare resource utilization and costs associated with subcutaneous versus intravenous administration of pertuzumab and trastuzumab from a societal perspective.

Methods

This study was conducted at two Dutch hospitals. Observational data were collected on drug preparation, administration times, and resource use for both formulations. Patient questionnaires assessed societal costs, including travel expenses and productivity losses. Costs were calculated for patient chair time, healthcare profess

SUBMITTER: Zietse M 

PROVIDER: S-EPMC12475515 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature